Skip to main content

Table 3 Effects of study medication on biomarker serum levels

From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Serum biomarker and study group Level changesa
Δδ day 14 of cycle 1 - baseline P value Δδ day 1 of cycle 2 - baseline P value Δδ day 1 of cycle 3 - baseline P value
VEGF-A Sunitinib -0.6816 (1.43) 0.017 -0.1393 (1.83) 0.831 0.1111 (1.26) 0.975
Placebo -0.3134 (1.24) 0.472 -0.7184 (1.32) 0.033 -1.1177 (1.92) 0.062
sVEGFR2 Sunitinib -0.0648 (0.17) 0.012 -0.0854 (0.12) 0.006 -0.0727 (0.14) 0.078
Placebo -0.0086 (0.12) 0. 222 -0.0216 (0.10) 0.472 0.0306 (0.20) 0.910
VEGF-D Sunitinib 0.2476 (0.26) <0.001 0.1038 (0.27) 0.131 0.0914 (0.20) 0.133
Placebo -0.1093 (0.66) 0.616 -0.0094 (0.19) 0.811 -0.1061 (0.25) 0.281
SDF-1α Sunitinib 0.0914 (0.47) 0.756 0.2912 (0.92) 0.730 - -
Placebo -0.0827 (0.93) 0.820 0.3572 (0.85) 0.041 - -
  1. aData are presented as mean (SD). P < 0.05 marked in boldface and considered significant using paired Wilcoxon test